Search PubMed⌕ Search

Biomedical subjects

R F Mould

Publications and source records attributed to R F Mould.

At least 55 records · Page 3Linked to original sources
PubMed1978

Recurrent genital candidosis in women and the effect of intermittent prophylactic treatment.

A study of clotrimazole for the treatment of recurrent genital candidosis unexpectedly showed that symptoms and infection can be dissociated. The aim of the study was to see if intermittent antifungal treatment would reduce symptoms in women constantly distressed by recurrent genital candidosis. Forty women seriously affected by the condition were initially given oral and local antifungal treatment. When the patients were symptom-free and the vagina was free of yeasts, they were entered into a double-blind clinical trial and were treated prophylactically for four months with either intermittent clotrimazole pessaries and cream or a placebo. The prophylactic treatment kept symptoms below a critical level but did not affect the return of the yeasts to the vagina. This dissociation between symptoms and vaginal yeasts was unexpected. Rectal yeast carriage was unaffected by prophylactic vaginal treatment. Male contacts and patients both showed a high incidence of non-specific genital infection. This association has seldom been reported. A few patients cultured yeasts from their homes but this environment was not considered a major source of reinfection. The vaginal pH did not appear to be altered by the presence of yeasts. The results of the study suggested that symptoms in women with recurrent genital candidosis were not caused by yeasts alone, and possibly the reason for recurrences might lie not in constant reinfection by yeasts, but in failure to recognise and remove a primary underlying factor, perhaps infection with other sexually transmitted agents. The question of a synergistic action between yeasts and other organisms is discussed.

Adult↗
PubMed1976

Calculation of survival rates by the life table and other methods.

The last few years have seen the introduction of medical statistics into the curriculum for MB, BS and for the FFR. Also, an increasing number of clinical trials have considered statistics at the planning stage of the trial, rather than only at the end point. However, there is one particular aspect of medical statistics which has consistently been neglected, namely, technique in calculating survival rates for cancer patients. All too often, a direct method of calculation, see section 3.1, is used when a life table method would provide a better estimate. The life table, or actuarial method, was first described in a medical context by Greenwood (1926), and later by Merrell and Shulman (1955) and Cutler and Ederer (1958). It has however, not been explained in detail in a British journal. The objective of the present paper is to remedy, this fact so that it can be used more widely in the future in preference to a direct method.

Humans↗
PubMed1976

Clinical trial of combination chemotherapy and specific active immunotherapy in disseminated melanoma.

Fifty-six patients with disseminated malignant melanoma were randomly allocated to two treatment groups. The first group C received combination chemotherapy consisting of DTIC and ICRF 159. The second group (C+I) received the same chemotherapy but were also immunized with 2 X 10(7) irradiated allogeneic melanoma cells mixed with 50 mug of percutaneous BCG. The survival rates in both treatment groups C and (C+I) were not significantly different, and only minor enhancement of the chemotherapy was found in the (C+I) group. A similar pattern of tissue response was observed in both groups: lymph node, skin and, to some extent liver metastases, respond better than other sites.

Antigens, Neoplasm↗
PubMed1976

Distribution of survival times of 12,000 head and neck cancer patients who died with their disease.

The lognormal parametric statistical model can provide, for groups of carcinoma cervix patients, good estimates of long-term survival fractions several years earlier than would otherwise be possible. The present paper extends this model work to head and neck cancer by using a minimum chi-squared test for goodness of fit (P greater than 0-05), to study the distribution of survival times of patients who died with their cancer present. Some 12,000 case histories were available from 7 hospital registries, 4 regional cancer registries and one national registry (the OPCS). All histories were followed up for at least 10 years subsequent to treatment and could be grouped into one of 8 cancer sites: antrum, floor of mouth, larynx, nasopharynx, pyriform fossa, post cricoid, tonsil and tongue. The theoretical distributions investigated were the lognormal, negative exponential and skew exponential. The results showed that the lognormal provided the best overall fit to the data, although the range of optimum values for the lognormal parameter, S, differed with cancer site. The optimum range did, however, usually include the value S=0-45. These results will now permit the second stage of validation of the lognormal model to proceed for head and neck cancers.

England↗
PubMed1976

New primary cancers in patients originally presenting with carcinoma of the cervix.

A total of 4502 patients with carcinoma of the cervix was studied: in 113 patients 116 other primary neoplasms were found and tumours of lung, breast, colon and rectum occurred most frequently. Most of the patients in our series died with the other primary present. Treatment of the cancer of the cervix by radiotherapy seemed to play no role in the induction of anot;er primary cancer.

Aged↗
PubMed1975

A test of several parametic statistical models for estimating success rate in the treatment of carcinoma cervix uteri.

The parametric statistical models discussed include all those which have previously been described in the literature (Boag, 1948-lognormal; Berkson and Gage, 1952-negative exponential; Haybittle, 1959-extrapolated actuarial) and the basic data used to test the models comprised some 3000 case histories of patients treated between 1945 and 1962. The histories were followed up during the period treated between 1945 and 1962. The histories were followed up during the period 1969-71 and thus provided adequate information to validate long-term survival fractions predicted using short-term follow-up data. The results with the log-normal model showed that for series of staged carcinoma cervix patients treated during a 5-year period, satisfactory estimates of long-term survival fractions could be predicted after a minimum waiting period of 3 years for stages I and II, and 2 years for stage III. The model should be used with a value assumed for the lognormal paramater S in the range S = 0.35 to S = 0.40. Although alternative models often gave adequate predictions, the lognormal proved to be the most consistent model. This model may therefore now be used with more confidence for prospective studies on carcinoma cervix series and can provide good estimates of long-term survival fractions several years earlier than would otherwise be possible.

Female↗